Information Provided By:
Fly News Breaks for February 17, 2017
PTLA
Feb 17, 2017 | 06:37 EDT
Citi analyst Yigal Nochomovitz raised his price target for Portola Pharmaceuticals to $39 saying his analysis indicates that the FDA no longer requesting an advisory panel for betrixaban is good news. The analyst raised the approval probability of the drug to 85% from 75%. Priority review and no panel is tied to a 94% approval probability, substantially higher than the 67% approval probability for priority review with a panel, Nochomovitz tells investors in a research note, citing his analysis. He keeps a Buy rating on Portola.
News For PTLA From the Last 2 Days
There are no results for your query PTLA